Cytogenetic and Fluorescence In Situ Hybridization Studies in Multiple Myeloma

Pts must be registered to and not yet have begun therapy on one of the following Southwest Oncology Group treatment protocols: S0115, S0232, S0340, S0417, and all new SWOG coordinated Multiple Myeloma, smoldering myeloma, Waldenstrom's Macroglobulinemia, monoclonal gammopathy of undetermined significance, or amyloidosis protocols activated on or after September 1, 2005. Pts who have already begun treatment on any of these trials are not eligible for enrollment to S0334. All pts must be informed of the investigational nature of this study, and must sign and give written informed consent in accordance with institutional and FDA guidelines. Consent for specimen submission will be obtained and documented with consent for the appropriate treatment protocol.